Bringing Precision Medicine to Brain Tumors
Therillume is a clinical-stage neuro-oncology therapeutics company bringing precision medicine to patients with Glioblastoma (GBM) and Neurofibromatosis Types 1 and 2 (NF1 and NF2). Therillume is a human therapeutic company, spinning out from Recombinetics Inc., and leveraging its pioneering precise gene-editing platform and intellectual property to identify, validate and expedite high-quality candidates through clinical development.
Our Founder and Chief Scientific Officer, Dr. Adrienne Watson, Discusses the Value of Large Animal Models in Neurofibromatosis Research
Women Researchers in NF - Adrienne L. Watson - Children's Tumor Foundation (ctf.org)
https://www.ctf.org/news/women-researchers-in-neurofibromatosis-nf-adrienne-l-watson/
FACING THE FACTS
Glioblastoma (GBM)
Neurofibromatosis Type 1 (NF1)
Seeking investment and strategic partnerships
Reach out today for information on how you can make a difference